Ibrutinib is an orally bioavailable, small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity.

Brigatinib is an orally available inhibitor of receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and the epidermal growth factor receptor (EGFR) with potential antineoplastic activity.

Saracatinib is a potent Src inhibitor

Dasatinib hydrochloride is a pyrimidine and thiazole derived antineoplastic agent and protein kinase inhibitor of BCR-ABL kinase.

TP0427736 is a potent inhibitor of ALK5 kinase activity

TP0427736 is a potent inhibitor of ALK5 kinase activity

GNF-2 is a highly selective non-ATP competitive inhibitor of Bcr-Abl, shows no activity to Flt3-ITD, Tel-PDGFR, TPR-MET and Tel-JAK1 transformed tumor cells.

IOX2 is a potent inhibitor of HIF-1α prolyl hydroxylase-2 (PHD2).